<DOC>
	<DOCNO>NCT01239654</DOCNO>
	<brief_summary>It exploratory study evaluate biological effect ( stent strut coverage ) use novel technology OCT without clinical implication .</brief_summary>
	<brief_title>Activity Platelets After Inhibition Cardiovascular Events Optical Coherence Tomography Study</brief_title>
	<detailed_description>The question whether DES safe , become area considerable interest controversy publication relatively small randomize trial ( BASKET-LATE ) , observational study meta-analysis reporting increase rate ST , MI , death DES compare BMS . The motivate factor presentation meta-analysis European Society Cardiology meeting Barcelona September 2006 , suggest increase risk death MI follow implantation sirolimus-eluting stent . The major issue meta-analyses limit either small sample size , duration follow-up , lack access source data , use landmark analysis exclude event first 6 month . Moreover , large meta-analysis DES vs. BMS SES vs. PES publish recently The Lancet Settler et al perform network analysis mixed-treatment comparison 38 randomize trial ( 18023 patient ) follow-up 4 year . This analysis confirm DES BMS associate similar rate overall cardiac mortality Regarding `` real world '' population , two observational registry recently publish , i.e . Western Denmark Heart Registry SCAAR ( Swedish Coronary Angiography Angioplasty Registry ) confirm difference hard endpoint DES BMS . However , must remember study observational best hypothesis-generating . Some autoptic study observe incomplete healing follow first generation DES implantation compare BMS ; series late ST associate delayed healing compare patent DES . Among unsettled fully test indication usage DES , ACS probably one implantation BMS remain used approach uncertainty regard thrombotic risk DES thrombus rich milieu low risk restenosis follow BMS implantation patient acute MI . Despite encouraging result currently publish data DES , well design appropriately powered clinical trial warrant order establish long term safety efficacy ( incremental advantage BMS ) DES setting . Moreover , recently report exposed strut frequent first generation DES , percent neointimal hyperplasia ( NIH ) area small ACS lesion non-ACS lesion . For specific purpose , evaluate , use OCT , complete neointimal coverage Everolimus- vs. Zotarolimus Eluting Stent implant novo lesion native coronary artery patient ACS . Rates expose and/or malaposed stent strut analyse neointimal hyperplasia ( NIH ) area calculate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis ACS clinical indication PCI Presence 1 de novo stenosis equal great 70 % native coronary artery . Patient &gt; 18 year age ( minimum age require local regulation ) . The patient consent participate signing `` Patient Informed Consent Form '' . The patient willing able cooperate study procedure require follow visit . Any type lesion include trial unless specifically detailed exclusion criterion . No stent implant target lesion Patients treat lesion venous arterial graft . Patients treat instent restenosis . Patients treat Unprotected Left Main lesion . Patients leave ventricular ejection fraction ( LVEF ) ≤30 % . Patients chronic kidney disease ( creatinine ≥1.5 mg/dL ) . Women known pregnancy lactate . Patients hypersensitivity allergy heparin , drug ABT578 everolimus , analogue derivative , cobalt , chromium , nickel , molybdenum contrast medium . Contraindication use clopidogrel and/or ASA : 1 . History drug allergy thienopyridine derivative ASA ; 2 . History clinically significant persistent thrombocytopenia neutropenia Active bleed significant risk bleeding , severe hepatic insufficiency , current peptic ulceration , proliferative diabetic retinopathy . Current medical condition life expectancy le 24 month . The subject participate another device drug study . Subject must complete followup phase previous study least 30 day prior enrolment trial . Patients medical condition preclude followup define protocol otherwise limit participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>acute</keyword>
	<keyword>coronary</keyword>
	<keyword>syndrome</keyword>
	<keyword>everolimus</keyword>
	<keyword>zotarolimus</keyword>
	<keyword>optical</keyword>
	<keyword>coherence</keyword>
	<keyword>tomography</keyword>
</DOC>